New hope for bladder cancer patients: immunotherapy may help avoid bladder removal
NCT ID NCT03697850
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether the immunotherapy drug atezolizumab can help control muscle-invasive bladder cancer in patients who cannot undergo bladder removal surgery. About 79 participants will receive atezolizumab after standard chemo-radiotherapy. The main goal is to see how long they remain cancer-free, with a focus on preserving the bladder.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Atezolizumab (an immunotherapy drug that helps the immune system fight cancer)
What this could lead to
If successful, this could offer a way to control bladder cancer without removing the bladder, potentially preserving quality of life for patients who are not candidates for surgery.
What could go wrong
This is an early-phase, single-arm study with only 79 participants, so results may not apply to all patients. Immunotherapy can cause side effects like inflammation in healthy organs, and the cancer may still return.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Antoine Lacassagne
Nice, France
-
Centre Azureen de Cancerologie
Mougins, 06250, France
-
Centre Georges Francois Leclerc
Dijon, France
-
Centre Jean Perrin
Clermont-Ferrand, France
-
Centre Oscar Lambret
Lille, France
-
Chu Lyon Sud
Pierre-Bénite, France
-
Gustave Roussy
Villejuif, 94800, France
-
Hopital Saint Louis
Paris, France
-
Hôpital Pitie Salpetriere
Paris, France
-
INSTITUT de CANCEROLOGIE DE L'OUEST - site René Gauducheau
Saint-Herblain, France
-
Icm Val D'Aurelle
Montpellier, France
-
Institut Bergonie
Bordeaux, France